The new service combines next-generation sequencing with latest microarray
HEIDELBERG, Germany, and LA JOLLA, Calif., Dec. 10 /PRNewswire/ -- Partnering with Prognosys Biosciences febit offers a new Genome-to-Array Service. This Service gives scientists access to the latest technology and know-how in sequencing and microarrays even for DNA where no standard microarrays are available. Using this service, scientists can go from biological genetic material to a working microarray experiment in weeks. Scientists in the field of microbial genomics for example now have a powerful and affordable tool for the analysis of unknown microbial DNA.
The Californian company Prognosys Biosciences contributes the sequencing of the organism's DNA by using next-generation sequencing. febit's Geniom Technology is used for preparative sample enrichment and supports the assembly process following sequencing. The data resulting from the next-generation sequencing procedure is the basis for synthesis of the biochip for microarray analysis. The biochip can be produced and analyzed in the Geniom One instrument either by the customer or as a service by febit.
In addition, febit will launch a new microarray analysis device in spring 2008, the Geniom RT Analyzer. The lower priced RT Analyzer enables customers to analyze Geniom Biochips, but does not include the ability to synthesize the chips themselves like the Geniom One product.
Anthony Caruso, Vice President Informatics & Application Software of febit inc., stated: "The powerful bioinformatics basis of the Geniom Technology enables us to offer this easy-to-use service to our customers for a very reasonable price."
About Prognosys Biosciences
Prognosys Biosciences, Inc. La Jolla (CA), is developing innovative assay technologies.
Developing innovative and creative technologies for genomic research is
the corporate mission of the febit group, a German-American biotech
company. Geniom is a technological and service platform successfully used
in basic and applied research of renowned institutions and companies.
Geniom exploits cutting-edge microarray technology for analysis and
synthesis of genes and genomes providing superior time and cost efficiency
combined with an unsurpassed spectrum of applications. With the Geniom
Technology febit now enters the high-potential market of synthetic biology
with a novel method for production of synthetic genes. Using both, highly
integrated automation and extensive customizability, febit meets essential
needs of current biomedical research.
febit holding gmbh Russo Partners, LLC
Eva Sterzel David Schull or Wendy Lau
Public Relations Manage +1-212-845-4271
+49 (6221) 6510-300 email@example.com
Copyright©2007 PR Newswire.
All rights reserved